Adamis Stock Jumps As Its Oral COVID-19 Drug Trial Starts Dosing

by Vandana Singh, Benzinga Editor

September 2, 2021 10:56 AM | 1 min read |

Adamis Pharmaceuticals Corporation ADMP has initiated dosing in the Phase 2/3 trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
The trial is designed to enroll 248 patients.
Related: Immunology Journal Publishes Data For Adamis' COVID-19 Candidate
An interim analysis by the data and safety monitoring board (DSMB) will examine safety and markers of systemic inflammation during a Stage 1 interim analysis.
Based on the DSMB analysis, the Phase 3 portion of the trial designed to enroll 198 patients may begin, with a second interim analysis planned after the enrollment of 124 patients.
Also Read: NIH Sees Promise in Tempol for COVID-19
Price Action: ADMP stock is up 2.70% at $1.14 during the market session on the last check Thursday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.